Everything below concerns peptidase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
In 2014, the European Association for Palliative Care recommended oxycodone by mouth as a second-line alternative to morphine by mouth for cancer pain. In children between 11 and 16, the extended-release formulation is FDA-approved for the relief of cancer pain, trauma pain, or pain due to major surgery (for those already treated with opioids, who can tolerate at least 20 mg per day of oxycodone) – this provides an alternative to Duragesic (fentanyl), the only other extended-release opioid analgesic approved for children. Oxycodone, in its extended-release form or in combination with naloxone, is sometimes used off-label in the treatment of severe and refractory restless legs syndrome.
Israel say the refusal was because they intended to spread hate speech against Israel. Elin Jones confirms she will stand down as Llywydd of the Senedd following the next election. 8 April – Downing Street declines calls to officially back a campaign to buy British goods in the wake of the introduction of US trade tariffs, arguing that the UK is "an open-trading nation" and the government is "not going to tell people where they buy their stuff". The European Court of Human Rights rules that businessman Sir Philip Green's human rights were not breached when he was named in the House of Lords in relation to misconduct allegations in 2018. He was named in Parliament under the rule of Parliamentary privilege, which allows Members of Parliament and peers to speak without the threat of legal repercussions. 9 April King Charles gives a speech to the Italian Parliament. He and Queen Camilla also have a private meeting with Pope Francis at Vatican City. Leader of the Fire Brigades Union Steve Wright calls on Labour MPs to reject benefit cuts. Councillor for Talbot and Branksome Woods on Bournemouth, Christchurch and Poole Council Karen Rampton resigns from the Conservative Party. The Welsh Government confirms that the Senedd will vote on whether the Terminally Ill Adults (End of Life) Bill should apply to Wales if it successfully passes through the Westminster parliament. 10 April – The Cabinet Office is to lose a third of its posts as part of government reforms to the civil service, with 2,100 of the 6,500 positions to be cut.
=== Esophageal and gastric variceal bleeding === For portal hypertension, nonselective beta blockers, such as propranolol or nadolol, are commonly used to lower blood pressure over the portal system. In severe complications from portal hypertension, transjugular intrahepatic portosystemic shunting (TIPS) is occasionally indicated to relieve pressure on the portal vein. As this shunting can worsen hepatic encephalopathy, it is reserved for those patients at low risk of encephalopathy. TIPS is generally regarded only as a bridge to liver transplantation or as a palliative measure. Balloon-occluded retrograde transvenous obliteration can be used to treat gastric variceal bleeding. Gastroscopy (endoscopic examination of the esophagus, stomach, and duodenum) is performed in cases of established cirrhosis. If esophageal varices are found, prophylactic local therapy may be applied, such as sclerotherapy or banding, and beta blockers may be used.
== Safety == Avobenzone is not generally recognised as safe and effective (GRASE) by the FDA for lack of sufficient data to support this claim. However, it is still the only FDA approved UVA filter (up to 3% concentration). Avobenzone is also approved in all other jurisdictions, such as EU (up to 5%), Australia, and Japan. A 2017 study at Lomonosov Moscow State University found that chlorinated water and ultraviolet light can cause avobenzone to disintegrate into various other organic compounds, including; phenolic acids, aldehydes, phenols, and acetophenones which can cause adverse health effects.
Sources: en.wikipedia.org
=== Hybrids === American black bears are reproductively compatible with several other bear species and occasionally produce hybrid offspring. According to Jack Hanna's Monkeys on the Interstate, a bear captured in Sanford, Florida, was thought to have been the offspring of an escaped female Asian black bear and a male American black bear. In 1859, an American black bear and a Eurasian brown bear were bred together in the London Zoo, but the three cubs that were born died before they reached maturity. In The Variation of Animals and Plants Under Domestication, Charles Darwin noted:
Protein misfolding cyclic amplification (PMCA) is an amplification technique (conceptually like polymerase chain reaction (PCR) but not involving nucleotides) to multiply misfolded prions originally developed by Soto and colleagues. It is a test for spongiform encephalopathies like chronic wasting disease (CWD) or bovine spongiform encephalopathy (BSE).
When it was known as Boston Chicken, restaurants specialized in rotisserie chicken and a variety of side dishes, but in February 1995, the chain expanded its menu to include turkey, meatloaf, and ham and changed the name to Boston Market in the fall of 1995 to reflect this. The corporate name remained Boston Chicken, Inc. until 1997, when the new name became popular and the corporate name was changed to Boston Market Corporation. In 1995, Boston Chicken created the Einstein Bros. Bagels chain of bakery cafés, after acquiring several smaller chains of bagel-centric bakeries. In 1996, the chain launched "Boston Carver Sandwiches", which featured chicken, turkey, ham, and meatloaf; in 1997, due to the success of the sandwich line, "Extreme Carver" sandwiches, filled with larger portions of meat and cheese, were launched. The company raised a lot of debt to finance its expansion. The rapid expansion allowed the company to create a steady stream of revenue from one-time development fees and increasing royalties, but also raised interest rates on its development loans. In 1998, the company filed for Chapter 11 bankruptcy. Since April 1999, a selection of Boston Market-branded items have been available in many supermarkets across the United States. Boston Market was purchased by McDonald's Corporation in May 2000, primarily for its real estate holdings. McDonald's found the brand serviceable, and continued to operate and expand Boston Market. In the early 2000s, Boston Market operated two locations in Toronto, Ontario.
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases.
Lorenzo Feritta, who at the time was one of the presidents of the UFC, said, "We want 100 percent of the fighters tested the night they compete". Also, in addition to the drug testing protocols in place for competitors on fight night, the UFC conducts additional testing for main event fighters or any fighters that are due to compete in championship matches. This includes enhanced, random 'out of competition' testing for performance-enhancing drugs, with both urine and blood samples being taken. The UFC also announced that all potential UFC signees would be subject to mandatory pre-contract screening for performance-enhancing drugs prior to being offered a contract with the promotion.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.